

Date: October 19, 2023

To,

NSE LIMITED

EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Sale/Disposal of entire stake held by the Company in its Associate Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the board of directors has approved to sale/dispose the entire stake i.e. 1868090 equity shares held by it in its Associate Company, Ratnatris Pharmaceuticals Private Limited ("RPPL"), by way of shares swap. Accordingly, RPPL will cease to be an Associate Company of the Company.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR / CFD / CMD / 4 / 2015, dated September 09, 2015, are given as an Annexure to this letter.

We request you to take the same on record.

Thanking you

Yours Sincerely,

For, Remus Pharmaceuticals Limited

SWAPNIL

JATINBHAI SHAH

Digitally signed by
SWAPNIL JATINBHAI SHAH
Date: 2023.10.19 15:26:31
+05'30'



Swapnil Jatinbhai Shah

Chairman and Whole Time Director

DIN: 05259821

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Annexure

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015

	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Ratnatris Pharmaceuticals Private Limited, was not an associate company during the financial year ended March 31,2023. Hence, amount and percentage of contribution is not applicable.
2.	Date on which the agreement for sale has been entered into	The Company will enter into a definitive agreement for Share Swap transaction with Senores Pharmaceuticals Limited (Transferee Company) upon approval of shares swap transaction by the members of Transferee Company.
3.	The expected date of completion of sale/ disposal.	Within 02 Months
4.	Consideration received from such sale/ disposal.	The Company shall receive 3261244 number of Equity Shares of Senores Pharmaceuticals Limited.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	The entire stake will be purchased by Senores Pharmaceuticals Limited (SPL). SPL belongs to the promoter group companies and the said transaction is done at the arms length basis. The transaction would be a related party transaction. The swap ratio has been determined based on the valuation report obtained from independent valuer.
6.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation / merger, shall be disclosed by the listed entity with respect to such slump sale	Not applicable

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536